Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stok Raporu

Piyasa değeri: US$65.6m

Zynerba Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Armando Anido

İcra Kurulu Başkanı

US$1.9m

Toplam tazminat

CEO maaş yüzdesi33.6%
CEO görev süresi9yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi6.8yrs
Yönetim Kurulu ortalama görev süresi8.2yrs

Son yönetim güncellemeleri

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23
Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

CEO Tazminat Analizi

Armando Anido'un ücretlendirmesi Zynerba Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$633k

-US$35m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$38m

Dec 31 2021US$2mUS$603k

-US$37m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$1mUS$585k

-US$51m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$45m

Mar 31 2020n/an/a

-US$36m

Dec 31 2019US$1mUS$568k

-US$33m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$36m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$568k

-US$40m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$41m

Mar 31 2018n/an/a

-US$37m

Dec 31 2017US$2mUS$552k

-US$32m

Sep 30 2017n/an/a

-US$31m

Jun 30 2017n/an/a

-US$28m

Mar 31 2017n/an/a

-US$26m

Dec 31 2016US$901kUS$536k

-US$23m

Tazminat ve Piyasa: Armando 'nin toplam tazminatı ($USD 1.88M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Armando 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Armando Anido (65 yo)

9yrs

Görev süresi

US$1,881,402

Tazminat

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Armando Anido
Chairman & CEO9yrsUS$1.88m1.94%
$ 1.3m
Terri Sebree
President9yrsUS$1.38m1.18%
$ 775.1k
James Fickenscher
CFO & VP of Corporate Development (Leave of Absence)7.1yrsUS$1.26m0.75%
$ 491.5k
Kenneth Jones
VP, Corporate Controller & Interim CFO6.6yrsVeri yok0.17%
$ 111.2k
Albert Parker
Chief Legal Officer & Corporate Secretary1.7yrsVeri yok0.45%
$ 295.1k
Joseph Apostolico
Vice President of Human Resources5.6yrsVeri yokVeri yok

6.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: ZYNE 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Armando Anido
Chairman & CEO9yrsUS$1.88m1.94%
$ 1.3m
Kenneth Moch
Independent Director8.2yrsUS$107.50k0.15%
$ 98.5k
Daniel Kisner
Independent Director8.2yrsUS$105.00k0.15%
$ 98.5k
Warren Cooper
Lead Independent Director8.2yrsUS$135.00k0.15%
$ 98.5k
John Butler
Independent Director5.5yrsUS$102.50k0.16%
$ 105.0k
William Federici
Independent Director8.2yrsUS$110.00k0.15%
$ 98.5k
Steven Siegel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Randi Hagerman
Member of Scientific Advisory Board8yrsVeri yokVeri yok
Elizabeth Berry-Kravis
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Nicole Tartaglia
Member of Scientific Advisory Board7yrsVeri yokVeri yok
Pamela Stephenson
Independent Director4.7yrsUS$100.00k0.15%
$ 98.5k
Craig Erikson
Member of Scientific Advisory Boardno dataVeri yokVeri yok

8.2yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ZYNE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.2 yıldır).